Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Bevacizumab Combined With Three Intra-arterial Therapies for Unresectable Hepatocellular Carcinoma
NCT07380633Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab and bevacizumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Sun Yat-sen University. Primary endpoint: 12-Month Progression-Free Survival Rate. Started Jan 2026; status: active, not recruiting.
02
Drugs
toripalimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07380633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380633.